ADPRS and cancer: Our research shows that combined ARH3 gene interruption and PARG inhibition sensitizes cancer cells to alkylating genotoxins, providing new insights into the role of protein ADP-de-ribosylation in DNA repair after alkylation-induced DNA damage and suggesting new potential drug combinations for therapy.